OMNIPAQUE 300 Drug Patent Profile

✉ Email this page to a colleague

When do Omnipaque 300 patents expire, and when can generic versions of Omnipaque 300 launch?

Omnipaque 300 is a drug marketed by Ge Healthcare and is included in two NDAs.

The generic ingredient in OMNIPAQUE 300 is iohexol. There are three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the iohexol profile page.

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for OMNIPAQUE 300?
What are the global sales for OMNIPAQUE 300?
What is Average Wholesale Price for OMNIPAQUE 300?

Summary for OMNIPAQUE 300

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	98
Clinical Trials:	25
Patent Applications:	3,518
DailyMed Link:	OMNIPAQUE 300 at DailyMed

Drug patent expirations by year for OMNIPAQUE 300

Recent Clinical Trials for OMNIPAQUE 300

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Fédération des médecins résidents du Québec	Phase 4
Centre for Interdisciplinary Research in Rehabilitation of Greater Montreal	Phase 4
Claire Bourgeois	Phase 4

See all OMNIPAQUE 300 clinical trials

Pharmacology for OMNIPAQUE 300

Drug Class	Radiographic Contrast Agent
Mechanism of Action	X-Ray Contrast Activity

US Patents and Regulatory Information for OMNIPAQUE 300

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ge Healthcare	OMNIPAQUE 300	iohexol	SOLUTION;INJECTION, ORAL, RECTAL	018956-003	Dec 26, 1985		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Ge Healthcare	OMNIPAQUE 300	iohexol	SOLUTION;INJECTION, ORAL, RECTAL	020608-002	Oct 24, 1995		RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for OMNIPAQUE 300

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ge Healthcare	OMNIPAQUE 300	iohexol	SOLUTION;INJECTION, ORAL, RECTAL	018956-003	Dec 26, 1985	⤷ Sign Up	⤷ Sign Up
Ge Healthcare	OMNIPAQUE 300	iohexol	SOLUTION;INJECTION, ORAL, RECTAL	018956-003	Dec 26, 1985	⤷ Sign Up	⤷ Sign Up
Ge Healthcare	OMNIPAQUE 300	iohexol	SOLUTION;INJECTION, ORAL, RECTAL	018956-003	Dec 26, 1985	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for OMNIPAQUE 300

See the table below for patents covering OMNIPAQUE 300 around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Netherlands	7905166		⤷ Sign Up
New Zealand	190907	PREPARATION OF X-RAY CONTRAST AGENT BY AUTOCLAVING A META-CARBOXAMIDO-ORTHO-IODO-N-(BETAHYDROXYALKYL)-ANILINE	⤷ Sign Up
Japan	S5531068	MANUFACTURE OF X RAY CONTRAST AGENT INJECTABLE STERILIZED SOLUTION	⤷ Sign Up
Spain	381202		⤷ Sign Up
Sweden	441181	NYA NONJONOGENA, JODHALTIGA FORENINGAR FOR ANVENDNING SOM RONTGENKONTRASTMEDEL	⤷ Sign Up
France	2354316		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for OMNIPAQUE 300

Recent Clinical Trials for OMNIPAQUE 300

Pharmacology for OMNIPAQUE 300

Make Better Decisions: Try a trial or see plans & pricing